Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study

Adrienne Y. L. Chan, Andrew S. C. Yuen, Daniel H. T. Tsai, Wallis C. Y. Lau, Yogini H. Jani, Yingfen Hsia, David P. J. Osborn, Joseph F. Hayes, Frank M. C. Besag, Edward C. C. Lai, Li Wei, Katja Taxis, Ian C. K. Wong () and Kenneth K. C. Man ()
Additional contact information
Adrienne Y. L. Chan: University of Groningen
Andrew S. C. Yuen: University College London
Daniel H. T. Tsai: St George’s University of London
Wallis C. Y. Lau: Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park
Yogini H. Jani: University College London
Yingfen Hsia: St George’s University of London
David P. J. Osborn: University College London
Joseph F. Hayes: University College London
Frank M. C. Besag: University College London
Edward C. C. Lai: National Cheng Kung University
Li Wei: University College London
Katja Taxis: University of Groningen
Ian C. K. Wong: Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park
Kenneth K. C. Man: Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park

Nature Communications, 2023, vol. 14, issue 1, 1-11

Abstract: Abstract Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-40637-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40637-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-40637-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().